case_images: PMC9299059_01
case_images: pCR to neoadjuvant alectinib in resectable ALK-positive NSCLC. Contrast-enhanced CT of the chest before neoadjuvant therapy showed an approximately 4.2 x 3.4 cm mass in the right hilum with localized obstructive pneumonia in the right lower lobe (A) and enlarged R4 lymph node (B); Contrast-enhanced CT of the chest after neoadjuvant therapy showed an approximately 1.2 x 1.1 cm mass in the right hilum, with a tumor shrinkage of 90% (C) and 0.6 x 0.6 cm R4 lymph node, with a shrinkage of 50% (D); Contrast-enhanced CT of the chest at the 8-month follow-up showed no local replase (E,F).
case_images: fphar-13-816683-g001.jpg
case_images: PMC9299059_01_fphar-13-816683-g001.jpg
case_images: F1
case_images: Contrast-enhanced computerized tomography (CT) of the chest showed an approximately 4.2 x 3.4 cm mass in the right hilum with localized obstructive pneumonia in the right lower lobe and multiple enlarged lymph nodes in the right hilum and mediastinum (Figure 1).
case_images: Pathologic findings of this patient. (A), Bronchoscopic biopsy of the mass before treatment showed poorly differentiated pulmonary adenocarcinoma (H&E, x 100); (B), Immunohistochemical testing results (D5F3 assay) confirmed strong positivity of ALK (x 100); (C), Postoperative pathology showed pathological complete response, with a downstaging to ypT0N0M0 (H&E, x 100).
case_images: fphar-13-816683-g002.jpg
case_images: PMC9299059_01_fphar-13-816683-g002.jpg
case_images: F2
case_images: Mucosal biopsy of the infiltrated lesion at the opening of the basal and dorsal segments of the right lower lobe showed poorly differentiated pulmonary adenocarcinoma with a Ki-67 of 35% (Figure 2).
case_images: The timeline therapy administration from the episode of care. PR, partial response; pCR, pathological complete response.
case_images: fphar-13-816683-g003.jpg
case_images: PMC9299059_01_fphar-13-816683-g003.jpg
case_images: F3
case_images: The timeline therapy administration from the episode of care was shown in Figure 3.